Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
4.320
-0.220 (-4.85%)
At close: Mar 6, 2026, 4:00 PM EST
4.650
+0.330 (7.64%)
After-hours: Mar 6, 2026, 4:35 PM EST
Neuphoria Therapeutics Revenue
Neuphoria Therapeutics had revenue of $14.99M in the twelve months ending December 31, 2025, up 2,161.41% year-over-year. In the fiscal year ending June 30, 2025, Neuphoria Therapeutics had annual revenue of $15.65M.
Revenue (ttm)
$14.99M
Revenue Growth
+2,161.41%
P/S Ratio
1.55
Revenue / Employee
$1,873,342
Employees
8
Market Cap
23.29M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNEUP News
- 3 months ago - Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees - GlobeNewsWire
- 3 months ago - Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium - GlobeNewsWire
- 3 months ago - Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions - GlobeNewsWire
- 3 months ago - Neuphoria Therapeutics Inc. Sends Letter to Stockholders - GlobeNewsWire
- 4 months ago - Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value - GlobeNewsWire
- 4 months ago - Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process - GlobeNewsWire
- 4 months ago - PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 4 months ago - Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder - GlobeNewsWire